Brief: Shenzhen Hepalink Pharmaceutical Unit Notified That U.S. FDA Approved New Drug Application
16/03/2023 12:36
March 16 (Reuters) - Shenzhen Hepalink Pharmaceutical Group
Co Ltd 002399.SZ :
* UNIT NOTIFIED U.S. FOOD AND DRUG ADMINISTRATION APPROVED
NEW
DRUG APPLICATION FOR ENOXAPARIN SODIUM INJECTION
Further company coverage: 002399.SZ
Recent news on Shenzhen Hepalink Pharmaceutical Co
See all newsBrief: Shenzhen Hepalink Pharmaceutical Group Says Enoxaparin Sodium Injection Obtains New Manufacturer Authorization From EMA
Brief: Shenzhen Hepalink Pharmaceutical Group Posts QTRLY Net Profit Attributable Of RMB156.6 Million
Brief: Shenzhen Hepalink Pharmaceutical Posts Profit Attributable RMB646.7 Million For Year
Brief: Shenzhen Hepalink Pharmaceutical Says Enoparin Approved In Argentina
Brief: Shenzhen Hepalink Pharmaceutical Says H1710 Injection Received Approval For From NMPA